课题基金 / 基金详情

ACTG 285 STEM CELL MOBILIZATION AND HARVESTING WITH FILGRASTIM

ACTG 285 STEM CELL MOBILIZATION AND HARVESTING WITH FILGRASTIM
使用 FILGRASTIM 动员和收获 ACTG 285 干细胞
批准号:
6114147
负责人:
Robert Turner Schooley
金额:
$3.22万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-12-01 至 1999-11-30

项目摘要

项目成果

Robert Turner Schooley的其他基金

相似基金

相关文献

中文摘要
翻译
ACTG 285 -使用非格司亭从外周血中动员和收获干细胞的初步研究。该研究探讨了非格司亭动员CD 34+干细胞进入外周血的能力是否在不同阶段的HIV-1感染个体和HIV-1血清阴性个体之间存在显著差异。该研究的目的是确定干细胞收获的安全性,并确定在HIV-1感染的各个阶段的受试者中给予非格司亭后,新鲜收获和冻存的干细胞的表面表型和功能特征,这些干细胞已动员到外周血中。这项试验的结果尚未公布。
英文摘要
ACTG 285 - A Pilot Study of Stem Cell Mobilization and Harvesting from the Peripheral Blood Using Filgrastim. The study explored whether the ability of Filgrastim to mobilize CD34+ stem cells into the peripheral blood differs markedly among individuals with various stages of HIV-1 infection and HIV-1 seronegative individuals. The study's objectives were to determine the safety of stem cell harvesting and to determine the surface phenotypic and functional characteristics of both freshly harvested and cryopreserved stem cells that have been mobilized into the peripheral blood subsequent to the administration of Filgrastim in subjects at various stages of HIV-1 infection. Results of this trial have not yet been published.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of Sustained-Release Anti-HIV Nucleoside Phosphonate Nanoparticles
Development of Sustained-Release Anti-HIV Nucleoside Phosphonate Nanoparticles
Development of Sustained-Release Anti-coronavirus Nucleoside Phosphonate compounds
Orally Active Nucleoside Phosphonates for Hepatitis C Virus
海外基金